Related Experiment Video
Updated: Sep 20, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Abstract:
In two ongoing phase I trials, PC14586, a Y220C-selective structural corrector of mutant p53, and BI 907828, an MDM2-p53 antagonist, appear safe and tolerable, showing signs of efficacy. These emerging data offer hope that a key tumor suppressor may not be as undruggable as previously thought.
More Related Videos
09:32Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
Published on: September 10, 2017
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
Related Concept Videos
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against...
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...